145 related articles for article (PubMed ID: 24419065)
1. Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study.
Montes Ramírez ML; Miró JM; Quereda C; Jou A; von Wichmann MÁ; Berenguer J; González-García JJ; Hernando A; Ortega E; Sanz J; Arribas JR;
J Acquir Immune Defic Syndr; 2014 Jan; 65(1):82-6. PubMed ID: 24419065
[TBL] [Abstract][Full Text] [Related]
2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
3. Incidence of hepatocellular carcinoma in hepatitis C cirrhotic patients with and without HIV infection: a cohort study, 1999-2011.
Di Benedetto N; Peralta M; Alvarez E; Schroder MT; Estepo C; Paz S; Fainboim H
Ann Hepatol; 2013 Jan-2014 Feb; 13(1):38-44. PubMed ID: 24378264
[TBL] [Abstract][Full Text] [Related]
4. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
Ganne-Carrié N; Chaffaut C; Bourcier V; Archambeaud I; Perarnau JM; Oberti F; Roulot D; Moreno C; Louvet A; Dao T; Moirand R; Goria O; Nguyen-Khac E; Carbonell N; Antonini T; Pol S; de Ledinghen V; Ozenne V; Henrion J; Péron JM; Tran A; Perlemuter G; Amiot X; Zarski JP; Beaugrand M; Chevret S;
J Hepatol; 2018 Dec; 69(6):1274-1283. PubMed ID: 30092234
[TBL] [Abstract][Full Text] [Related]
5. No increased risk of hepatocellular carcinoma in cirrhosis due to Wilson disease during long-term follow-up.
van Meer S; de Man RA; van den Berg AP; Houwen RH; Linn FH; van Oijen MG; Siersema PD; van Erpecum KJ
J Gastroenterol Hepatol; 2015 Mar; 30(3):535-9. PubMed ID: 25160780
[TBL] [Abstract][Full Text] [Related]
6. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
7. Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis.
Benmassaoud A; Nitulescu R; Pembroke T; Halme AS; Ghali P; Deschenes M; Wong P; Klein MB; Sebastiani G
Clin Infect Dis; 2019 Sep; 69(8):1422-1430. PubMed ID: 30561558
[TBL] [Abstract][Full Text] [Related]
8. Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India.
Paul SB; Sreenivas V; Gulati MS; Madan K; Gupta AK; Mukhopadhyay S; Panda SK; Acharya SK
Indian J Gastroenterol; 2007; 26(6):274-8. PubMed ID: 18431010
[TBL] [Abstract][Full Text] [Related]
9. Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis.
García-García JA; Romero-Gómez M; Girón-González JA; Rivera-Irigoin R; Torre-Cisneros J; Montero JL; González-Serrano M; Andrade RJ; Aguilar-Guisado M; Grilo I; Martín-Vivaldi J; Salmerón J; Caballero-Granado FJ; Macías J; Vergara-López S; Pineda JA; ;
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1236-41. PubMed ID: 17209765
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
11. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
[TBL] [Abstract][Full Text] [Related]
12. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
[TBL] [Abstract][Full Text] [Related]
13. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model.
Flemming JA; Yang JD; Vittinghoff E; Kim WR; Terrault NA
Cancer; 2014 Nov; 120(22):3485-93. PubMed ID: 25042049
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
Kramer JR; El-Serag HB; Taylor TJ; White DL; Asch SM; Frayne SM; Cao Y; Smith DL; Kanwal F
J Viral Hepat; 2017 Nov; 24(11):955-965. PubMed ID: 28815822
[TBL] [Abstract][Full Text] [Related]
15. Impact of Alcohol Abstinence on the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Cirrhosis.
Rodríguez M; González-Diéguez ML; Varela M; Cadahía V; Andrés-Vizán SM; Mesa A; Castaño A; Alvarez-Navascués C
Am J Gastroenterol; 2021 Dec; 116(12):2390-2398. PubMed ID: 34569986
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study.
Zhang H; Zhu J; Xi L; Xu C; Wu A
World J Surg Oncol; 2019 Apr; 17(1):75. PubMed ID: 31039803
[TBL] [Abstract][Full Text] [Related]
17. The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population-based cohort study.
Bengtsson B; Widman L; Wahlin S; Stål P; Björkström NK; Hagström H
United European Gastroenterol J; 2022 Jun; 10(5):465-476. PubMed ID: 35491484
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.
Chen TH; Chen CJ; Yen MF; Lu SN; Sun CA; Huang GT; Yang PM; Lee HS; Duffy SW
Int J Cancer; 2002 Mar; 98(2):257-61. PubMed ID: 11857416
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
20. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
